Corpus Intelligence IC Memo — SHASTA REGIONAL MEDICAL CENTER 2026-04-26 15:12 UTC
IC Memo — SHASTA REGIONAL MEDICAL CENTER
Investment Committee Memorandum | CA | 205 beds | Grade C | EBITDA uplift $12.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SHASTA REGIONAL MEDICAL CENTER

CCN 050764 | SHASTA, CA | 205 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SHASTA REGIONAL MEDICAL CENTER is a 205-bed rural/critical access in SHASTA, CA with $162.4M in net patient revenue and a -4.5% operating margin. The hospital serves a payer mix of 52.8% Medicare, 5.4% Medicaid, and 41.8% commercial.

Thesis: Undervalued. Our ML models identify $12.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -4.5% to 2.9% (+736bps).

Net Revenue HCRIS$162.4M
Current EBITDA COMPUTED$-7.2M
Operating Margin COMPUTED-4.5%
Occupancy HCRIS31.8%
Revenue / Bed COMPUTED$792K
Net-to-Gross HCRIS18.8%
Distress Probability ML53.4%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
218
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -4.5% places it above the state median. Among 218 size-comparable peers (102-410 beds), the median margin is -4.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (102-410), prioritizing same-state peers. 218 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SHASTA REGIONAL MEDICAL CENTER (Target)CA205$162.4M-4.5%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%
HARBOR-UCLA MEDICAL CENTERCA369$1.54B-6.4%
EL CAMINO HOSPITALCA388$1.34B11.7%
CHILDRENS HOSPITAL OF ORANGE CCA334$1.31B0.7%
KFH - SANTA CLARACA343$1.25B12.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $12.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.4M+210bp18mo
Cost to Collect4.5%2.5%$3.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.0M+122bp9mo
Clean Claim Rate88.0%96.0%$104K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.4M
Cost to Collect
$3.2M
Denial Rate Reduction
$3.2M
A/R Days Reduction
$2.0M
Clean Claim Rate
$104K
Total EBITDA Uplift$12.0M
Current EBITDA$-7.2M
+ RCM Uplift+$12.0M
Pro Forma EBITDA$4.7M
Current Margin-4.5%
Pro Forma Margin2.9%
WC Released (1x)$6.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-11.1M$71.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-11.1M$75.4M0.00x-100.0%
Bull Case9.0x11.0x$-10.0M$111.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-10.0M$118.4M0.00x-100.0%
Bear Case11.0x10.0x$-12.2M$15.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-12.2M$13.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 31.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 53.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 218 hospitals with 102-410 beds
  • Same-state prioritization (n=219)
  • Comp margins: P25=-16.7% / P50=-4.1% / P75=4.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.